Analyst Ratings for [ASND] Ascendis Pharma A/S - ADS

1/7/25	Initiated	Buy	X
ASND Ascendis Pharma UBS
$196
9/5/24	Upgrades	Perform Outperform	X
ASND Ascendis Pharma Oppenheimer
$180
6/25/24	Upgrades	Hold Buy	X
ASND Ascendis Pharma TD Cowen
$156 $175
5/31/24	Initiated	Buy	X
ASND Ascendis Pharma Stifel
$200
6/14/23	Resumed	Neutral	X
ASND Ascendis Pharma Credit Suisse
$89
4/5/23	Downgrades	Outperform Perform	X
ASND Ascendis Pharma Oppenheimer
4/4/23	Downgrades	Overweight Eq-Weight	X
ASND Ascendis Pharma Morgan Stanley
$151 $108
4/3/23	Downgrades	Outperform Neutral	X
ASND Ascendis Pharma Credit Suisse
10/20/22	Initiated	Buy	X
ASND Ascendis Pharma Goldman
$174
8/30/22	Resumed	Buy	X
ASND Ascendis Pharma Berenberg
$166
3/28/22	Resumed	Outperform	X
ASND Ascendis Pharma Wedbush
$163
3/15/22	Upgrades	Neutral Buy	X
ASND Ascendis Pharma BofA Securities
$148 $161
1/6/22	Initiated	Market Perform	X
ASND Ascendis Pharma Cowen
$136
12/8/21	Initiated	Overweight	X
ASND Ascendis Pharma Wells Fargo
$176
10/20/21	Downgrades	Buy Neutral	X
ASND Ascendis Pharma BofA Securities
$164 $169
3/30/21	Downgrades	Outperform Perform	X
ASND Ascendis Pharma Oppenheimer
3/11/21	Resumed	Buy	X
ASND Ascendis Pharma Stifel
$190
3/25/19	Initiated	Outperform	X
ASND Ascendis Pharma Evercore ISI
1/24/19	Initiated	Overweight	X
ASND Ascendis Pharma Cantor Fitzgerald
$102
1/24/19	Upgrades	Mkt Perform Outperform	X
ASND Ascendis Pharma Leerink Partners
6/26/18	Initiated	Buy	X
ASND Ascendis Pharma Stifel
$85
4/2/18	Reiterated	Mkt Perform	X
ASND Ascendis Pharma Leerink Partners
$37 $64

ASND Ascendis Pharma A/S - ADS

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.